A Phase 1 interventional study of ruxolitinib and gemcitabine in Solid Tumors and Pancreatic Cancer, sponsored by Incyte Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies testing gemcitabine in Pancreatic Neoplasms — 30 open to participants now, 45 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.
Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 152nd largest by enrollment of the 353 interventional ones that give a count, is one of 19 that started in 2013, is one of 87 in phase 1, and was the 228th registered.
3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →30 of the 370 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 126 · Phase 2 239 · Phase 3 36 · Phase 4 2
First in 1995; this study’s year is marked. 19 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 353 interventional studies. Of the 268 that completed or were terminated, 80 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 370 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
10 studies in Pancreatic Neoplasms by Incyte Corporation: 1 open now, 2 under way, 1 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 8th largest by enrollment, is one of 3 that started in 2013, is one of 3 in phase 1, and was the 2nd registered.
Incyte Corporation’s Pancreatic Neoplasms studies by the year they started, since 2011.
15 of the studies testing gemcitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT03652428University of Maryland, BaltimorePhase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | 2026-12-31 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, from their registry updates:
Among Incyte Corporation’s 10 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study of ruxolitinib in combination with gemcitabine with or without nab-paclitaxel administered to patients with advanced or metastatic pancreatic cancer. The study will be conducted in two parts.
Part 1 of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of ruxolitinib when given as described to patients with advanced or metastatic pancreatic cancer. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of ruxolitinib when given with gemcitabine with or without nab-paclitaxel. This dose will be selected for use in Part 2 of the study.
Part 2 of the study will further evaluate the safety, tolerability, PK and preliminary clinical activity of ruxolitinib at the dose defined in Part 1 used in combination with gemcitabine with or without nab-paclitaxel in subjects with advanced or metastatic pancreatic cancer.
After multiple challenges of trial conduct, by mutual agreement between investigators and sponsor, dose escalation ended after Cohort B1, RUX 10 mg twice daily (BID) - GCSF in October 2014. Therefore, the MTD was not reached. No safety issues led to the decision to stop further enrollment.
Because of the early study termination, samples for pharmacokinetics and pharmacodynamics, and computed tomography for tumor burden were collected, but not analyzed; analysis data are not available. The data cutoff for this posting is 22 SEP 2015. As of the data cutoff, 1 subject was receiving treatment in the study and had been enrolled for 47 weeks. This subject had their end of treatment visit in AUG 2016. A comparison of this subjects' safety data after the cutoff date showed no clinically meaningful differences (eg, adverse events) compared with safety results that are summarized here.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Requirements for prior therapy as outlined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
Drug: ruxolitinib · Drug: gemcitabine
Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored. nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
Drug: ruxolitinib · Drug: gemcitabine · Drug: nab-paclitaxel · Drug: filgrastim
Other names: Gemzar®
Other names: Abraxane®
Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
Also known as: Neupogen®
Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)
Toxicities occurring during the first treatment cycle (Cycle 1) defined tolerability. Within each cohort, subjects were considered evaluable if they had received at least 40 of 56 planned doses of RUX during the 28-day surveillance period and received 2 of the 3 planned doses of chemotherapy (gemcitabine and/or gemcitabine and nab-paclitaxel) at the assigned dose level, or they had experienced a DLT.
Time frame: Approximately 28 days
Plasma Concentrations Will be Used to Estimate Peak Plasma Concentration (Cmax) and Area Under the Plasma Concentration Curve (AUC).
Time frame: Day 1 and Day 8
Plasma Concentration of Tumor Specific Biomarkers and Cytokines Before and During Treatment.
Time frame: Up to 6 months
Clinical Activity as Measured by the Greatest Decrease in Tumor Burden Compared to Baseline.
Time frame: Approximately 6 months
Percentage of Participants With a Best Response by RECIST Criteria
Best response was determined on the subject level using the highest overall response achieved post-baseline. In the case of stable disease (SD), measurements had to meet the SD criterion at least once after study entry at a minimum interval of 49 days. Subjects who failed to meet this criterion had best response of progressive disease (PD) if the next available RECIST evaluation after the initial scan indicated PD or not evaluable (NE) if no additional RECIST evaluations were available. Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.
Time frame: every 2 cycles starting at Cycle 3 Day 1 up to approximately 4 to 6 months
Percentage of Responders
Duration of response was measured as the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response.
Time frame: Randomization to clinical cutoff 22Sept2015 (approx 244 days)
Duration of Response
Duration of response was the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response. Confidence intervals for median duration of response were calculated using the method of Brookmeyer and Crowley (1982).
Time frame: Randomization to clinical cutoff 22Sept2015 (approx 244 days)
| Milestone | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| Started | 16 | 4 | 10 | 4 | 8 |
| Discontinued from the study | 16 | 4 | 10 | 4 | 7 |
| Completed | 0 | 0 | 0 | 0 | 1 |
| Not completed | 16 | 4 | 10 | 4 | 7 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Disease progression | 11 | 1 | 7 | 2 | 6 |
| Withdrew: Death | 2 | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Disease progression & patient preference | 2 | 0 | 1 | 0 | 0 |
Toxicities occurring during the first treatment cycle (Cycle 1) defined tolerability. Within each cohort, subjects were considered evaluable if they had received at least 40 of 56 planned doses of RUX during the 28-day surveillance period and received 2 of the 3 planned doses of chemotherapy (gemcitabine and/or gemcitabine and nab-paclitaxel) at the assigned dose level, or they had experienced a DLT.
| percentage of participants | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs) | 0.0 | 0.0 | 20.0 | 50.0 | 0.0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Best response was determined on the subject level using the highest overall response achieved post-baseline. In the case of stable disease (SD), measurements had to meet the SD criterion at least once after study entry at a minimum interval of 49 days. Subjects who failed to meet this criterion had best response of progressive disease (PD) if the next available RECIST evaluation after the initial scan indicated PD or not evaluable (NE) if no additional RECIST evaluations were available. Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.
| percentage of participants | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| Overall response | 12.5 | 25.0 | 50.0 | 25.0 | 37.5 |
| Complete response | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 |
| Partial response | 12.5 | 25.0 | 50.0 | 0.0 | 37.5 |
| Stable disease | 25.0 | 75.0 | 20.0 | 50.0 | 25.0 |
| Progressive disease | 37.5 | 0.0 | 10.0 | 0.0 | 37.5 |
| Not evaluable | 6.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Missing | 18.8 | 0.0 | 20.0 | 25.0 | 0.0 |
Duration of response was measured as the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response.
| Percentage of responders | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| Percentage of Responders | 12.5 | 25.0 | 50.0 | 25.0 | 37.5 |
Duration of response was the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response. Confidence intervals for median duration of response were calculated using the method of Brookmeyer and Crowley (1982).
| days | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| Duration of Response | 132.0 (NA to NA) | 33.0 (NA to NA) | 113.0 (57.0 to 533.0) | 244.0 (NA to NA) | 225.0 (57.0 to 225.0) |
Collected over From randomization to 30 days after last visit up to approximately 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A0 | — | 10/16 (62.5%) | 16/16 (100%) |
| Cohort B (-1) | — | 4/4 (100%) | 4/4 (100%) |
| Cohort B0 (+GCSF) | — | 3/10 (30%) | 10/10 (100%) |
| Cohort B0 (-GCSF) | — | 0/4 (0%) | 4/4 (100%) |
| Cohort B1 | — | 2/8 (25%) | 8/8 (100%) |
| Event | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/16 | 1/4 | 0/10 | 0/4 | 1/8 |
| Abdominal painGastrointestinal disorders | 4/16 | 0/4 | 0/10 | 0/4 | 0/8 |
| Duodenal ulcer hemorrhageGastrointestinal disorders | 0/16 | 1/4 | 0/10 | 0/4 | 0/8 |
| AstheniaGeneral disorders | 0/16 | 1/4 | 0/10 | 0/4 | 1/8 |
| Pharyngeal abscessInfections and infestations | 0/16 | 1/4 | 0/10 | 0/4 | 0/8 |
| Urinary tract infectionInfections and infestations | 0/16 | 1/4 | 0/10 | 0/4 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 1/16 | 1/4 | 0/10 | 0/4 | 1/8 |
| DiarrheaGastrointestinal disorders | 0/16 | 0/4 | 0/10 | 0/4 | 1/8 |
| Eye infection toxoplasmalInfections and infestations | 0/16 | 0/4 | 0/10 | 0/4 | 1/8 |
| SepsisInfections and infestations | 2/16 | 0/4 | 0/10 | 0/4 | 0/8 |
| Event | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 9/16 | 2/4 | 6/10 | 4/4 | 3/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/16 | 1/4 | 6/10 | 4/4 | 1/8 |
| FatigueGeneral disorders | 10/16 | 4/4 | 8/10 | 2/4 | 5/8 |
| NauseaGastrointestinal disorders | 4/16 | 3/4 | 8/10 | 2/4 | 3/8 |
| NeutropeniaBlood and lymphatic system disorders | 3/16 | 2/4 | 2/10 | 3/4 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 2/16 | 3/4 | 5/10 | 1/4 | 2/8 |
| Oedema peripheralGeneral disorders | 4/16 | 3/4 | 5/10 | 2/4 | 4/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/16 | 0/4 | 2/10 | 3/4 | 3/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/16 | 2/4 | 2/10 | 3/4 | 1/8 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/16 | 3/4 | 7/10 | 1/4 | 4/8 |
Intent-to-Treat Subjects (ITT): All subjects who received at least 1 dose of Ruxolitinib (RUX).
| Age, Continuous(years) | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 | Total |
|---|---|---|---|---|---|---|
| Mean | 62.6 ± 8.56 | 61.3 ± 6.40 | 61.2 ± 9.33 | 70.0 ± 7.62 | 62.4 ± 8.48 | 62.8 ± 8.45 |
| Sex: Female, Male(Participants) | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 4 | 6 | 0 | 2 | 20 |
| Male | 8 | 0 | 4 | 4 | 6 | 22 |
| Eastern Cooperative Oncology Group (ECOG) performance status(participants) | Cohort A0 | Cohort B (-1) | Cohort B0 (+GCSF) | Cohort B0 (-GCSF) | Cohort B1 | Total |
|---|---|---|---|---|---|---|
| 0 | 6 | 2 | 8 | 3 | 5 | 24 |
| 1 | 10 | 2 | 2 | 1 | 3 | 18 |
| 2 | 0 | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Apr 2013, a primary completion of Sep 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ruxolitinib · Gemcitabine